title: Trabecular bone volume and osteoprotegerin expression in uremic rats given high calcium.
abstract: Calcium (Ca)-containing phosphate binders have been recommended for the treatment of hyperphosphatemia in children with chronic kidney disease. To study the effects of high Ca levels on trabecular bone volume (BV) and osteoprotegerin (OPG) expression in uremic young rats, a model of marked overcorrection of secondary hyperparathyroidism was created by providing a diet of high Ca to 5/6 nephrectomized young rats (Nx-Ca) for 4 weeks. The results of chondrocyte proliferation and apoptosis, osteoclastic activity, OPG expression and BV were compared among intact rats given the control diet, intact rats given a high Ca diet and 5/6 nephrectomized rats given the control diet (Nx-Control) and the high Ca diet (Nx-Ca). Ionized Ca levels were higher and parathyroid hormone levels were lower in Nx-Ca rats than in the other groups. Final weight, final length and final tibial length of Nx-Ca rats were significantly less than those of the other groups, although the length gain did not differ among the groups. The hypertrophic zone width was markedly enlarged in Nx-Ca rats. Chondrocyte proliferation rates did not differ among the groups, whereas osteoclastic activity was decreased in Nx-Ca rats compared with the Nx-Control animals. The OPG expression and BV were increased in Nx-Ca rats compared with the Nx-Control rats. Increased BV should improve bone strength, whereas disturbance of osteoclastogenesis interferes with bone remodeling. Bone quality has yet to be determined in high Ca-fed uremic young rats.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, 10330, Thailand. Pornpimol.r@chula.ac.th
authors.forename: Pornpimol
authors.initials: P
authors.lastname: Rianthavorn
authors.forename: Robert B
authors.initials: RB
authors.lastname: Ettenger
authors.forename: Isidro B
authors.initials: IB
authors.lastname: Salusky
authors.forename: Beatriz D
authors.initials: BD
authors.lastname: Kuizon
mesh_terms: D000818:Animals; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D002118:Calcium / Q000494:pharmacology*; D002136:Calcium, Dietary / Q000008:administration & dosage / Q000494:pharmacology; D019902:Chondrocytes / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D006962:Hyperparathyroidism, Secondary / Q000150:complications / Q000378:metabolism; D054559:Hyperphosphatemia / Q000150:complications; D008297:Male; D009392:Nephrectomy; D053244:Osteoprotegerin / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D014511:Uremia / Q000503:physiopathology*
chemical_list: D002136:Calcium, Dietary; D053244:Osteoprotegerin; D002118:Calcium